WntResearch AB completed a Phase 1 clinical trial with its first drug candidate, Foxy-5. The company is
about to embark on an intensive clinical development phase when shortly starting up a Phase 1b study, while
continuing to plan for the subsequent Phase 2 study. With the high intensity of work right now, the current CEO
Nils Brunner has expressed strong desires to the Board to have full focus only on the clinical development and
thus relinquish the administrative responsibility of the company. The Board has therefore appointed Henrik
Lawaetz as the new CEO for WntResearch, effective from 1 January 2016. Nils Brunner will henceforth be
responsible for, and focus primarily on the company's clinical development program as Chief Medical Officer
(CMO).